Please assess the completion status of the following clinical trial:

Trial Title: A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects, younger than 12 years old.~* Severe hemophilia B (Factor IX \[FIX\] activity of ≤ 2%).~* Body weight ≥ 10 kg.~* Subjects who have received FIX products (plasma-derived and/or recombinant FIX) for \> 150 exposure days (EDs) (6 to \< 12 years), and \> 50 EDs (\< 6 years).~* No history of FIX inhibitor formation, no detectable inhibitors at Screening and no family history of inhibitors against FIX.~* Written informed consent for study participation.~Exclusion Criteria:~* Known hypersensitivity to any FIX product or hamster protein.~* Known congenital or acquired coagulation disorder other than congenital FIX deficiency.~* Kidney or liver disease.~* Recent life-threatening bleeding episode.

- Gender: MALE
- Minimum Age: None
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- rIX-FP (Type: EXPERIMENTAL): Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) will be administered by IV infusion as routine weekly prophylaxis and episodic treatment for bleeding episodes.

Based on this trial design, predict the completion outcome and termination type (if applicable).